Immuno Diagnostix (IDX) - An ultrasensitive, low cost photonic biosensor

免疫诊断 (IDX) - 超灵敏、低成本光子生物传感器

• 批准号: EP/V047434/1
• 负责人: Thomas Krauss
• 金额: $ 122.75万
• 依托单位: University of York
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FV047434%2F1
• 关键词: Immuno; Diagnostix; IDX; ultrasensitive; low

Around 400,000 people in the UK live with rheumatoid arthritis (RA). RA is an inflammatory disease that affects the joints, causing swelling, restricted movement and pain. Although there is no cure for RA, there are today a wide variety of treatments that can help reduce inflammation, relieve pain and minimise joint damage. Given the wide number of treatments, how do we know which treatment is the best for each individual patient? Furthermore, the drugs used to treat RA can have detrimental side effects, including cardiovascular disease and a higher susceptibility to infection. It is therefore critical that patients are monitored regularly to check whether their treatments are working and that the side effects of their medication are reduced. At present, this is done using blood tests which are usually performed every month at the hospital. However, the frequency of these tests leads to disruption to patients who are often functionally incapacitated by their disease, and significant costs to the NHS. In the last few years, there has been increasing interest in reducing the number and frequency of patient visits through the introduction of technology that would enable remote monitoring. The advent of the COVID-19 pandemic has accelerated the need for this technology, as telephone or internet-based appointments have become the norm and it is desirable to not have immunocompromised patients attending medical centers for blood tests.We previously demonstrated a new diagnostic technology that can detect and quantify the proteins in blood that are used to check the efficacy of RA treatments. This diagnostic technology, called a guided mode resonance (GMR) sensor chip, is based on an optical diffraction grating that is rendered sensitive to specific proteins by grafting of antibodies on the sensor surface. Unlike traditional blood tests, our technology only requires very small volumes of blood (just a fingerprick), can be performed by non-specialists, potentially even the patient themselves, and only requires very low cost components. Despite this, the sensitivity of the technology is comparable to the larger, more complicated systems currently used for blood tests in hospitals. To date, this new technology has been shown to work well in trials in our dedicated laboratories. In this project, we will work with industrial partners to develop the technology, involving clinicians specialising in RA and with RA patients themselves, so it can be used to allow blood testing remotely. Specifically, we will design, build and test a small, low-cost instrument that is capable of reading the sensor chip and quantifying the protein concentration. At the same time, we will construct a simple microfluidic device that is capable of accepting a droplet of blood from a fingerprick, delivering the sample to the sensor for analysis and counting the number of white and red blood cells. Finally, we will test the device using blood samples from RA patients and compare our new technology to tests performed in the hospital using established methods.

英国约有 40 万人患有类风湿性关节炎 (RA)。 RA 是一种影响关节的炎症性疾病，会导致肿胀、活动受限和疼痛。尽管类风湿性关节炎无法治愈，但目前有多种治疗方法可以帮助减少炎症、缓解疼痛并最大程度地减少关节损伤。鉴于治疗方法多种多样，我们如何知道哪种治疗方法最适合每个患者？此外，用于治疗类风湿性关节炎的药物可能会产生有害的副作用，包括心血管疾病和更高的感染易感性。因此，定期监测患者以检查他们的治疗是否有效以及药物的副作用是否减少至关重要。目前，这是通过血液检查来完成的，通常每月在医院进行一次。然而，这些测试的频率会导致经常因疾病而丧失功能的患者受到干扰，并给 NHS 带来巨大成本。在过去几年中，人们越来越关注通过引入远程监控技术来减少患者就诊的数量和频率。 COVID-19大流行的出现加速了对这项技术的需求，因为基于电话或互联网的预约已成为常态，并且最好不要让免疫功能低下的患者去医疗中心进行血液检查。我们之前展示了一种新的诊断技术，可以检测和量化血液中的蛋白质，用于检查 RA 治疗的疗效。这种诊断技术称为导模共振 (GMR) 传感器芯片，基于光学衍射光栅，通过在传感器表面移植抗体，该光栅对特定蛋白质敏感。与传统的血液测试不同，我们的技术只需要非常少量的血液（只需刺一下指尖），可以由非专家甚至患者自己进行，并且只需要非常低成本的组件。尽管如此，该技术的灵敏度与目前医院用于血液检测的更大、更复杂的系统相当。迄今为止，这项新技术已在我们专门实验室的试验中表现良好。在这个项目中，我们将与工业合作伙伴合作开发该技术，包括专门从事 RA 的临床医生以及 RA 患者本身，因此该技术可用于远程血液检测。具体来说，我们将设计、构建和测试一种小型低成本仪器，该仪器能够读取传感器芯片并量化蛋白质浓度。同时，我们将构建一个简单的微流体装置，能够接受指尖刺破的血滴，将样本输送到传感器进行分析并计算白细胞和红细胞的数量。最后，我们将使用 RA 患者的血液样本测试该设备，并将我们的新技术与医院使用既定方法进行的测试进行比较。

项目成果

Multiplexed Near-Field Optical Trapping Exploiting Anapole States.

• DOI: 10.1021/acsnano.3c03100
• 发表时间: 2023-09-12
• 期刊: ACS NANO
• 影响因子: 17.1
• 作者: Conteduca, Donato;Brunetti, Giuseppe;Barth, Isabel;Quinn, Steven D. D.;Ciminelli, Caterina;Krauss, Thomas F. F.
• 通讯作者: Krauss, Thomas F. F.

Dielectric metasurface for high-precision detection of large unilamellar vesicles

• DOI: 10.1088/2040-8986/ac2dd7
• 发表时间: 2021-11-01
• 期刊: JOURNAL OF OPTICS
• 影响因子: 2.1
• 作者: Conteduca, D.;Quinn, S. D.;Krauss, T. F.
• 通讯作者: Krauss, T. F.

Dielectric nanohole array metasurface for high-resolution near-field sensing and imaging.

用于高分辨率近场感测和成像的介电纳米阵阵列递质。

• DOI: 10.1038/s41467-021-23357-9
• 发表时间: 2021-06-02
• 期刊: Nature communications
• 影响因子: 16.6
• 作者: Conteduca D;Barth I;Pitruzzello G;Reardon CP;Martins ER;Krauss TF
• 通讯作者: Krauss TF

Perturbation approach to improve the angular tolerance of high-Q resonances in metasurfaces.

提高超表面中高 Q 值共振的角度容差的扰动方法。

• DOI: 10.1364/ol.475601
• 发表时间: 2022
• 期刊: Optics letters
• 影响因子: 3.6
• 作者: Arruda GS

Beyond Q: The Importance of the Resonance Amplitude for Photonic Sensors.

• DOI: 10.1021/acsphotonics.2c00188
• 发表时间: 2022-05-18
• 期刊: ACS PHOTONICS
• 影响因子: 7
• 作者: Conteduca, Donato;Arruda, Guilherme S.;Barth, Isabel;Wang, Yue;Krauss, Thomas F.;Martins, Emiliano R.
• 通讯作者: Martins, Emiliano R.